Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran.
Nabavi SM, Mehrabani M, Ghalichi L, Nahayati MA, Ghaffari M, Ashtari F, Mohammadianinejad SE, Karimi S, Faghani L, Yazdanbakhsh S, Najafian A, Shahpasand K, Vosough M. Nabavi SM, et al. Among authors: nahayati ma. Vaccines (Basel). 2022 Jan 17;10(1):135. doi: 10.3390/vaccines10010135. Vaccines (Basel). 2022. PMID: 35062796 Free PMC article.
Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics.
Ghadiri F, Sahraian MA, Razazian N, Ashtari F, Poursadeghfard M, Nabavi SM, Navardi S, Baghbanian SM, Shaygannejad V, Harirchian MH, Beladimoghadam N, Majdinasab N, Hosseini S, Azimi A, Kamali H, Sharifipour E, Hosseini Nejad Mir N, Bayati A, Nahayati MA, Heidari H, Mozhdehipanah H, Ghalyanchi Langroodi H, Jalali N, Ayoubi S, Asadollahzadeh E, Ebadi Z, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Among authors: nahayati ma. Mult Scler Relat Disord. 2023 Feb;70:104493. doi: 10.1016/j.msard.2022.104493. Epub 2022 Dec 29. Mult Scler Relat Disord. 2023. PMID: 36638768
Iranian specialists' approach to surgery in patients with multiple sclerosis.
Ghadiri F, Ebadi Z, Asadollahzadeh E, Sahraian MA, Azimi A, Navardi S, Heidari H, Abna Z, Aboutorabi M, Adibi I, Baghbanian SM, Paybast S, Poursadeghfard M, Hosseini S, Shahmohammadi S, Ghaffari M, Ghalyanchi-Langroodi H, Ghiasian M, Kamali H, Kouchaki E, Mahrabi F, Mohammadianinejad E, Nahayati MA, Moghadasi AN. Ghadiri F, et al. Among authors: nahayati ma. Curr J Neurol. 2023 Apr 4;22(2):96-102. doi: 10.18502/cjn.v22i2.13336. Curr J Neurol. 2023. PMID: 38011379 Free PMC article.
Iranian specialists' approach to treatment escalation in multiple sclerosis patients with cognitive impairment.
Ghadiri F, Asadollahzadeh E, Ebadi Z, Sahraian MA, Azimi A, Navardi S, Heidari H, Abna Z, Aboutorabi M, Adibi I, Baghbanian SM, Paybast S, Poursadeghfard M, Hosseini S, Shahmohammadi S, Ghaffari M, Ghalyanchi-Langroodi H, Ghiasian M, Kamali H, Kouchaki E, Mahrabi F, Mohammadianinejad E, Nahayati MA, Moghadasi AN. Ghadiri F, et al. Among authors: nahayati ma. Curr J Neurol. 2023 Jan 5;22(1):1-7. doi: 10.18502/cjn.v22i1.12610. Curr J Neurol. 2023. PMID: 38011357 Free PMC article.
Investigation of the safety of live attenuated varicella-zoster virus vaccination in patients with relapse-remitting multiple sclerosis treated with natalizumab: A case series and review of the literature.
Paybast S, Sahraian MA, Nahayati MA, Habibi MA, Shahmohammadi S, Navardi S. Paybast S, et al. Among authors: nahayati ma. Mult Scler Relat Disord. 2023 Sep;77:104793. doi: 10.1016/j.msard.2023.104793. Epub 2023 Jun 2. Mult Scler Relat Disord. 2023. PMID: 37413854 Review.
Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.
Abbasi Kasbi N, Ghadiri F, Sahraian MA, Nahayati MA, Moghadasi AN, Langroodi HG, Poursadeghfard M, Hosseini S, Heidari H, Baghbanian SM, Kamali H, Ameli Z, Shahmohammadi S, Navardi S. Abbasi Kasbi N, et al. Among authors: nahayati ma. Acta Neurol Belg. 2024 Feb;124(1):205-212. doi: 10.1007/s13760-023-02366-z. Epub 2023 Sep 15. Acta Neurol Belg. 2024. PMID: 37715074 Clinical Trial.
16 results